The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor‐positive breast cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0215|137|3|686-697

ISSN： 0020-7136

Source： INTERNATIONAL JOURNAL OF CANCER, Vol.137, Iss.3, 2015-08, pp. : 686-697

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Fatty Acid Synthase Is a Potential Therapeutic Target in Estrogen Receptor-/Progesterone Receptor-Positive Endometrioid Endometrial Cancer

By  

Oncology, Vol. 84, Iss. 3, 2013-01 ,pp. : 166-173

Karger

Access to resources Recommend Favorite

Estrogen Receptor-Positive and Estrogen Receptor-Negative Human Breast Cancer Cells: Regulation of Expression of Cancer-Related Genes by Estradiol and Tamoxifen

By  

Current Signal Transduction Therapy, Vol. 3, Iss. 1, 2008-01 ,pp. : 7-21

Bentham Science Publishers

Access to resources Recommend Favorite

Active smoking and the risk of estrogen receptor‐positive and triple‐negative breast cancer among women ages 20 to 44 years

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 1026-1034

John Wiley & Sons Inc

Access to resources Recommend Favorite

The 21-Gene Recurrence Score Assay (Oncotype DX™) in Estrogen Receptor-Positive Male Breast Cancer: Experience in an Israeli Cohort

By  

Oncology, Vol. 87, Iss. 1, 2014-06 ,pp. : 1-6

Karger

Access to resources Recommend Favorite

The Preoperative Neutrophil/Lymphocyte Ratio Does not Correlate with the 21-Gene Recurrence Score in Estrogen Receptor-Positive Breast Cancer Patients

By  

Oncology Research and Treatment, Vol. 38, Iss. 1-2, 2015-01 ,pp. : 24-27

Karger

Access to resources Recommend Favorite